Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314
NCT ID: NCT04871646
Last Updated: 2021-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
586 participants
INTERVENTIONAL
2021-06-30
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497
NCT03726853
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
NCT05897541
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
NCT05305547
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
NCT04347915
A Trial of Remdesivir in Adults With Severe COVID-19
NCT04257656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKD-314
Treatment with CKD-314 + SOC
CKD-314+SOC
CKD-314 is administered intravenously and standard of care is also performed.
CKD-314 Placebo
Treatment with CKD-314 Placebo + SOC
CKD-314 Placebo+SOC
CKD-314 placebo is administered intravenously and standard of care is also performed..
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-314+SOC
CKD-314 is administered intravenously and standard of care is also performed.
CKD-314 Placebo+SOC
CKD-314 placebo is administered intravenously and standard of care is also performed..
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed with COVID-19 infection and pneumonia
3. Patients who have voluntarily decided to participate in the study and signed the informed consent form If a patient cannot provide consent on his or her own, informed consent by a legally authorized representative may be obtained.
Exclusion Criteria
2. Female patients, either who are or may be pregnant or who are breastfeeding, or female patients of child-bearing potential who are unable to use adequate contraception during the study
3. Patients who are deemed to ineligible to participate in the study for other reasons by the investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hee Jin Jung, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hee Jin Jung
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A108_02CVD2105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.